Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aquestive Therapeutics Inc (NQ: AQST )

5.270 -0.170 (-3.13%)
Streaming Delayed Price Updated: 11:03 AM EST, Jan 20, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aquestive Therapeutics Inc

< Previous 1 2 Next >
Aquestive Therapeutics Provides Business Update
From GlobeNewswire News Releases
Aquestive Therapeutics to Present at Two Upcoming Investor Conferences
From GlobeNewswire News Releases
Aquestive Therapeutics Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer
From GlobeNewswire News Releases
Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
From GlobeNewswire News Releases
Aquestive Therapeutics Receives First Milestone Payment from KYNMOBI™ Monetization
Receives first milestone payment of $10 million, bringing total fourth quarter proceeds to $50 million 
From GlobeNewswire News Releases
Aquestive Therapeutics Completes FDA Type A Meeting on Libervant
From GlobeNewswire News Releases
Aquestive Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Aquestive Therapeutics Signs Royalty Monetization Agreement with Marathon Asset Management for up to $125 Million
From GlobeNewswire News Releases
Aquestive Therapeutics to Announce Third Quarter Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET
From GlobeNewswire News Releases
Aquestive Therapeutics Receives Complete Response Letter from FDA for Libervant™ (diazepam) Buccal Film for Management of Seizure Clusters
From GlobeNewswire News Releases
Aquestive Therapeutics Initiates Phase 1 Pharmacokinetic Trial of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) In Development for Treatment of Allergic Reactions Including An
From GlobeNewswire News Releases
Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Treatment of Allergic Reactions Including Anaphylaxis
From GlobeNewswire News Releases
Aquestive Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update: AQST-108 Progress Remains On Track; Libervant PDUFA Goal Date Approaches
From GlobeNewswire News Releases
Aquestive Therapeutics to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
From GlobeNewswire News Releases
Aquestive Therapeutics to Announce Second Quarter Financial Results and Recent Business Highlights on Aug 4 and Host Conference Call on Aug 5 at 8:00 a.m. ET
From GlobeNewswire News Releases
Aquestive Therapeutics Files IND for Pharmacokinetic Clinical Trials of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis Treatment
From GlobeNewswire News Releases
Aquestive Therapeutics to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference
From GlobeNewswire News Releases
Aquestive Therapeutics to Hold Virtual-Only Annual Meeting of Stockholders
Notice of Change of Location of Annual Meeting of Stockholders to be held on June 16, 2020 to Virtual-Only Meeting 
From GlobeNewswire News Releases
Thinking about buying stock in Xeris Pharmaceuticals, Aquestive Therapeutics, Navidea Biopharmaceuticals, Sundial Growers, or Hexo Corp?
InvestorsObserver issues critical PriceWatch Alerts for XERS, AQST, NAVB, SNDL, and HEXO. 
From PR Newswire
Aquestive Therapeutics Advances Royalty Monetization Plan as Sunovion Pharmaceuticals’ Apomorphine Sublingual Film Therapy Receives FDA Approval
From GlobeNewswire News Releases
Thinking about trading stocks and options in Arcturus Therapeutics, Novavax, Spirit Airlines, Aquestive Therapeutics, or Penn National Gaming?
InvestorsObserver issues critical PriceWatch Alerts for ARCT, NVAX, SAVE, AQST, and PENN. 
From PR Newswire
Aquestive Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare Conference
From GlobeNewswire News Releases
Aquestive Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update: AQST-108 and Libervant Remain On Track
From GlobeNewswire News Releases
Aquestive Therapeutics to Announce First Quarter Financial Results and Recent Business Highlights on May 5 and Host Investment Community Conference Call on May 6
From GlobeNewswire News Releases
Memgen Appoints Gregory Brown as Chief Executive Officer
Tags Pharmaceuticals and Biotech
From Latest Press Releases from Newswire.com
Memgen Appoints Gregory Brown as Chief Executive Officer
From Newsfile Corp News Releases
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
From GlobeNewswire News Releases
Aquestive Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights on March 12, 2020
From GlobeNewswire News Releases
Aquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film
From GlobeNewswire News Releases
Aquestive Therapeutics Announces FDA Confirmed 505(b)(2) Pathway for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis Treatment
From GlobeNewswire News Releases
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.